Purnomo Hery D, Kusuma Refani A, Sianturi Elfrida, Haroen Ryan F, Solichin Muchamad R, Nissa Choirun, Pramono Adriyan, Mahati Endang, Noer Etika R
Division of Gastroentero-Hepatology, Department of Internal Medical, Dr Kariadi Hospital, Faculty of Medicine, Diponegoro University, Semarang 50275, Indonesia.
Department of Nutrition Science, Faculty of Medicine, Diponegoro University, Semarang 50275, Indonesia.
J Nutr Metab. 2023 Sep 14;2023:2313503. doi: 10.1155/2023/2313503. eCollection 2023.
Liver damage characterized by fibrosis and necrosis can worsen the condition of liver disease. Liver disease is associated with impaired immune response and may affect short-chain fatty acid (SCFA) gut metabolites. Hepatogomax enteral formula was developed, which contains brain-chain amino acids (BCAAs) and middle-chain triglycerides (MCTs), which could repair liver tissue damage, improve the inflammatory status, and modulate SCFA in liver damage. The study aimed to determine the effect of hepatogomax on liver tissue repair, inflammation (TNF- and IL-6), and SCFA levels in thioacetamide (TAA)-induced rats. The induction of TAA causes liver steatosis, increasing TNF- and IL-6, and decreasing SCFA levels. Hepatogomax at a dose of 14.6 g/200 gBW significantly reduces TNF- and IL-6 levels and increases SCFA levels ( < 0.05). The number of steatosis between groups P2 and P3 was lower as compared to a group of negative control [K2] ( < 0.05). Hepatogomax, in a dose-dependent manner, may repair liver tissue and improve inflammatory response and SCFA levels in TAA-induced rats.
以纤维化和坏死为特征的肝损伤会使肝脏疾病的病情恶化。肝脏疾病与免疫反应受损有关，并且可能会影响肠道短链脂肪酸（SCFA）代谢产物。研发了Hepatogomax肠内配方，其含有支链氨基酸（BCAAs）和中链甘油三酯（MCTs），能够修复肝组织损伤、改善炎症状态并调节肝损伤中的SCFA。该研究旨在确定Hepatogomax对硫代乙酰胺（TAA）诱导的大鼠肝组织修复、炎症（TNF-和IL-6）以及SCFA水平的影响。TAA诱导会导致肝脏脂肪变性，使TNF-和IL-6升高，并降低SCFA水平。剂量为14.6 g/200 gBW的Hepatogomax可显著降低TNF-和IL-6水平，并提高SCFA水平（P<0.05）。与阴性对照组[K2]相比，P2组和P3组之间的脂肪变性数量更低（P<0.05）。Hepatogomax可能以剂量依赖的方式修复TAA诱导的大鼠肝组织，并改善炎症反应和SCFA水平。
